[Monoclonal antibodies in the treatment of recurrent polyposis rhinosinusitis. Literature review].

This article is devoted to the problem of the effectiveness of therapy of recurrent polyposis rhinosinusitis and the choice of the most effective drug from the group of monoclonal antibodies. The wide prevalence of the disease, as well as the low level of effectiveness of existing treatment methods, such as glucocorticosteroid (topical and topical) therapy, antibacterial therapy and available surgical methods of treatment (polypotomy, endoscopic polysinusitomy) allow us to conclude that the existing methods of treatment for recurrent polyposis process do not allow to achieve a stable positive result. Various undesirable phenomena with prolonged use of steroidal drugs, as well as the need for repeated rhinosinusosurgery in case of recurrence of this process, make doctors-otorhinolaryngologists around the world to look for new treatment options for polyposis rhinosinusitis, one of these methods is the use of monoclonal antibodies. Currently, the treatment of recurrent polyposis rhinosinusitis is the most urgent task at the junction of two specialties: otorhinolaryngology and allergology-immunology. Polyposis rhinosinusitis has different courses. The phenotype most prone to recurrent growth of nasal polyps and the formation of concomitant bronchial asthma is induced by Th-2 immune response. In this case, the above-mentioned methods of treatment do not always help to achieve a stable remission. Monoclonal antibodies can be an additional method of treatment in this situation, which targetingly block certain parts of the Th2-inflammatory reaction, thereby controlling the symptoms. However, the increasing number of available monoclonal antibody preparations creates a problem of choosing the most optimal one. Due to the fact that biological therapy offers great therapeutic opportunities in modern clinical practice, further study and development of this direction in otorhinolaryngology is necessary.